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Summary A total of 468 cases of bone, soft tissue and visceral sarcomas (and certain other tumours)
diagnosed during the years 1982-84 in North West England were entered in a study of histopathological peer
review, incidence and survival. This paper describes the effects of peer review. Material was reviewed by a
panel of five pathologists for 413 of the 450 cases originally registered as sarcomas with the Regional Cancer
Registry. The diagnosis of sarcomas was confirmed in 76% cases and and there was agreement on sub-type for
53% cases. Measures of agreement were lowest for the two sub-types most commonly diagnosed i.e. malignant
fibrous histiocytoma and leiomyosarcoma. Degree of agreement between individual pathologists and final
panel diagnosis was also very variable but never less than 65%. It is concluded that second opinion is essential
in cases of presumed sarcomas for studies of incidence and aetiology and to ensure that appropriate treatment
is selected.
Bone and soft tissue sarcomas are rare tumours accounting
for less than 1% of all malignancies (Muir et al., 1987).
Accurate diagnosis of sub-type of sarcoma is important in
studies of incidence and aetiology, and also in terms of
clinical management of patients. Diagnosis, however, is often
extremely difficult and made more so because the rarity of
certain sub-types of sarcoma results in relatively few cases
being seen by any individual pathologist. In addition, criteria
for diagnosis of sub-type have changed markedly over the
last few decades and some are relatively newly defined. Even
with the advent of immunohistochemical techniques, a cer-
tain proportion of cases remain unclassifiable, and there may
be difficulties in distinguishing sub-types of similar
appearance.
The consequences of some of these problems are exempli-
fied in the results of the peer review studies of sarcomas
which have been undertaken (Baker et al., 1978; Presant et
al., 1986; Newton et al., 1988; Shiraki et al., 1989; Alvegard
& Berg, 1989). In these series histological sub-type of sar-
coma was frequently changed on review and significant pro-
portions of tumours were considered ineligible as sarcomas.
The study undertaken here was an attempt to define
accurately the incidence of sub-types of sarcomas in a
population-based series from North West England. This
paper describes the results of case review by a panel of five
pathologists.
Methods
Listings were obtained of all cases registered as sarcomas
with the North Western Regional Cancer Registry for the
years 1982, 1983 and 1984. In addition all cancer registra-
tions for these years were scrutinised individually to identify
cases not officially registered as sarcomas but where sarcoma
was mentioned as a differential diagnosis in the pathology
report or was recorded as part of death certification.
Cases included in the study were those malignant soft
tissue sarcomas given in the modified WHO scheme described
by Enzinger and Weiss (1988) together with certain primary
bone tumours i.e. osteosarcoma, chondrosarcoma, Ewing's
tumour and other primary sarcomas of bone. Sarcomas aris-
ing in the gastro-intestinal tract, the female genital tract and
other visceral sites were also included. Several other types of
tumours were included where the diagnosis of sarcoma was a
possibility e.g. giant cell tumour of bone, or where degree of
malignancy is often uncertain i.e. haemangiopericytoma,
haemangioendothelioma, atypical fibroxanthoma. Tumours
of mesothelial origin i.e. mesothelioma, and certain mixed
neoplasms e.g. carcinosarcoma and Miillerian mixed tumour
were excluded from the study.
Histopathological material was requested for each case in
the form of unstained slides or representative blocks. A copy
of the original histology report was also obtained. Initially
slides were stained with haematoxylin and eosin and were
circulated, together with a brief clinical summary of the case,
to the five panel members each of whom had a special
interest in sarcomas. The summary was compiled from details
given on the original pathology request form and from in-
formation on the cancer registration form; patient medical
notes were seen only where difficulty was experienced in
locating material.
The five panel members recorded their diagnoses indivi-
dually, without discussion or knowledge of the original histo-
logy, and returned their reports which were then circulated to
all members. Where all panel members offered the same
diagnosis this was recorded as the final (panel) diagnosis.
Where there was any disagreement between panel members'
diagnoses, cases were discussed at meetings where slides were
available, and a final consensus arrived at. In the case of
continuing diagnostic difficulty or where a major change in
diagnosis was contemplated the use of special stains includ-
ing immunohistochemistry was agreed and there was further
discussion of ssch cases at subsequent meetings. In the
majority of cases where difficult or contentious diagnoses
were under consideration, it was possible to perform appro-
priate immunohistochemical studies.
Other stains used were reticulin (Gordon & Sweet's
method), Masson's trichome, PAS and diastase-PAS, Alcian
blue and hyaluronidase-Alcian blue and PTAH. In addition,
immunohistochemical stains were employed as appropriate,
using either the PAP or ABC techniques. The antigens
detected were vimentin, desmin, cytokeratins (using CAM 5.2
and CKI), leucocyte common antigen, S-100 protein,
epithelial membrane antigen, factor VIII-related antigen,
neurone-specific enolase, muramidase and xlanti-trypsin.
CAM 5.2 was supplied by Becton-Dickinson; all other
antibodies were supplied by DAKO. Electron microscopy
was used in a few cases where appropriate, but none of the
cases was subjected to cytogenetic analysis.
Grade of malignancy was not specified but in smooth
muscle tumours where malignancy was equivocal, mitotic
counts were performed using the criteria for malignancy
recommeded by Enzinger and Weiss (1988).
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Final diagnoses were coded using ICD-O (WHO, 1976) to
enable comparison with the original diagnoses as recorded by
the cancer registry. Sub-categories were created for variants
of certain tumours which did not have specific ICD-O codes
e.g. variants of malignant fibrous histiocytoma, liposarcoma
and chondrosarcoma. ICD-O code 95403 was applied to
neurofibrosarcoma and malignant Schwannoma and all
tumours of this type were described as malignant peripheral
nerve sheath tumours.
Individual panel member's initial diagnoses were also com-
pared with the final diagnosis for each case and coded to
indicate varying levels of agreement with the final diagnosis
i.e. whether the material being reviewed was considered to be
neoplastic, malignant, of bone or soft tissue origin and, if a
specific histological diagnosis was offered, whether or not this
agreed with the final diagnosis of the panel. Panel members
were judged to have agreed with the final diagnosis if the
stated sub-type was the same, or if one of only two
differential diagnoses offered included the final diagnosis
(agreement type A), or if three or more differential diagnoses
offered included the final diagnosis (agreement type B).
The statistical software package SPSS/PC + was used to
construct frequency tables and cross-tabulations (Norusis,
1989). The original cancer registry diagnoses were compared
between the group of cases that were reviewed and the group
that were not using the chi-square test. The percentage of
reviewed cases with an original diagnosis of sarcoma that
had a final diagnosis of sarcoma was calculated as was the
percentage of reviewed cases with an original diagnosis of a
specific type of sarcoma that had the same final diagnosis.
For certain types of sarcoma a two by two table was
constructed of original diagnosis against final diagnosis, both
partitioned according to whether or not the diagnosis was the
particular type of sarcoma under consideration, and Cohen's
kappa (Fleiss, 1981) was used to measure the degree of
agreement between the cancer registry and panel. Cohen's
kappa takes a value of zero for chance agreement and a
value of one for perfect agreement. For reviewed cases with a
final diagnosis of sarcoma, the percentages which were
identified as neoplastic, as malignant and as sarcoma prior to
panel review were calculated separately for each pathologist.
Similarly for all reviewed cases with a final diagnosis of a
specific type of sarcoma and for certain sub-types of sarcoma
the percentage agreement with the final diagnosis was cal-
culated for each pathologist.
Results
The total number of cancer registrations scrutinised for the
study was 59,784 (19,550 for 1982, 19,980 for 1983 and
20,254 for 1984). Of these 450 cases were registered as sar-
comas. A further five cases were selected for review because
of possible uncertainty in diagnosis or in grade of malig-
nancy (two giant cell tumours of bone, and one each of
haemangioendothelioma, haemangiopericytoma and atypical
fibroxanthoma). In addition, 13 cases not registered as sar-
comas but where the possibility of sarcoma was mentioned
on the registration form, were included for review (eight
carcinomas, one seminoma, one lymphoma, one neurofibro-
matosis and two malignant tumours NOS). Hence a total of
468 cases was entered in the study. Bone tumours accounted
for 92 cases and soft tissue tumours for the remaining 376.
The original recorded histology for all cases is shown in
Table I.
Histopathological material was received and processed for
429 cases (metastatic tumour only was available for 11 of
these). In four cases, material was received but no sections of
tumour could be obtained from the blocks. No material was
received for 12 cases and four further cases proved to have
been incorrectly registered as sarcomas on scrutiny of the
original pathology report and so material was not processed.
Diagnosis of sarcoma had been made on clinical grounds in
19 individuals. Of the 429 cases processed 415 (96.7%) were
reviewed by all five pathologists. Because of limited
Table I Cases included in study by
diagnosis
original cancer registry
Histology Total (1982-84)
Soft tissue tumours
Sarcoma NOS 81
Leiomyosarcoma
Gastro-intestinal tract 17
Female genital tract 28
Soft tissue 21
Other sites 2
Malignant fibrous histiocytoma 52
Liposarcoma 38
Fibrosarcoma 27
Rhabdomyosarcoma 25
Haemangiosarcoma 14
Neurofibrosarcoma 10
Endometrial stromal sarcoma 10
Synovial sarcoma 7
Extra-skeletal chondrosarcoma 6
Malignant mesenchymoma 5
Other specified soft tissue sarcoma 18
Other tumours included in study
Carcinoma 7
Seminoma 1
Lymphoma I
Malignant tumour NOS 2
Atypical fibroxanthoma I
Haemangioendothelioma NOS 1
Haemangiopericytoma NOS 1
Neurofibromatosis 1
Total soft tissue tumours 376
Bone tumours
Osteosarcoma 40
Chondrosarcoma 27
Ewing's tumour 9
Sarcoma NOS 6
Chordoma 4
Fibrosarcoma 1
Leiomyosarcoma 1
Haemangiosarcoma 1
Giant cell tumour of bone 2
Metastatic carcinoma 1
Total bone tumours 92
Total 468
availability of some material, six (1.4%) were seen by only
four pathologists, six (1.4%) by three and the remaining two
(0.5%) by two pathologists.
Final diagnoses were arrived at by the panel for 421 of
the 429 reviewed cases. The broad histological categories of
the final diagnoses were as follows: sarcoma, specified histo-
logy 279; sarcoma NOS 36; connective tissue tumour of
borderline malignancy 12; benign connective tissue tumour
13; carcinoma 29; other specified malignant tumour 20;
malignant tumour NOS 23; non-neoplastic condition nine;
and non-diagnosable material eight. Of the five cases
included because of possible uncertainty in diagnosis the
original diagnoses of giant cell tumour of bone and atypical
fibroxanthoma were confirmed, the case of haemangioperi-
cytoma could only be defined as a borderline soft tissue
tumour and no tumour tissue was obtained for the case of
haemangioendothelioma. Hence none of these five cases
contributed to the final total of sarcomas. For the 13 cases
not registered as sarcomas but included in the study
because of mention of sarcoma on the registration form,
only two had a final diagnosis of sarcoma, one previously
diagnosed as malignant spindle cell tumour and another as
transitional cell carcinoma.
Of the 421 cases with agreed final diagnoses, 315 were
confirmed as sarcomas by the panel, 58 of bone and 257 of
soft tissue. Table II lists the final panel diagnoses for the 315
sarcoma cases. A more detailed description of incidence of
histological sub-types will be presented elsewhere. Histo-
logical diagnoses for the 93 cases originally registered asPEER REVIEW OF SARCOMAS 317
sarcomas but where sarcoma was not confirmed are shown in
Table III.
The clinically diagnosed cases consisted of nine oesteosar-
coma, nine sarcoma not otherwise specified and one chor-
doma. Because of this distribution the original cancer registry
Table II Final diagnoses for cases diagnosed by the panel as
sarcomas
Histology Total (1982-84)
Soft tissue tumours
Leiomyosarcoma
Gastro-intestinal tract 14
Female genital tract 20
Soft tissue 34
Other sites 4
Malignant fibrous histiocytoma 49
Sarcoma NOS 35
Liposarcoma 21
Malignant peripheral nerve sheath tumour 14
Rhabdomyosarcoma 11
Haemangiosarcoma 10
Endometrial stromal sarcoma 9
Synovial sarcoma 5
Other specified soft tissue sarcoma 31
Total soft tissue tumours 257
Bone tumours
Osteosarcoma 24
Chondrosarcoma 22
Ewing's tumour 8
Malignant fibrous histiocytoma I
Haemangiosarcoma 1
Chordoma I
Sarcoma NOS 1
Total bone tumours 58
Total sarcomas 315
Table III Final diagnoses for cases diagnosed by the panel as
non-sarcomas
Histology Total (1982-84)
Malignant tumours
Carcinoma NOS 11
Squamous cell carcinoma 8
Clear cell adenocarcinoma 2
Hepatocellular carcinoma I
Renal cell carcinoma I
Malignant melanoma 4
Mixed Mullerian tumour 8
Yolk sac tumour I
Astrocytoma I
Lymphoma 5
Malignant tumour NOS 21
Borderline tumours
Smooth muscle tumour of uncertain 3
malignant potential
Epithelioid leiomyoma 1
Cellular leiomyoma I
Haemangiopericytoma NOS 3
Benign tumours
Fibrous histiocytoma I
Lipoma 2
Leiomyoma 3
Bizarre leiomyoma 2
Capillary haemangioma I
Juxtacortical chondroma I
Neurofibroma 2
Benign soft tissue tumour NOS I
Non-neoplastic conditions
Proliferative myositis I
Fibrous dysplasia I
Fibromatosis NOS 4
Nodular fasciitis I
Non-neoplastic NOS I
Normal cellular morphology I
Total 93
diagnoses in the sample of cases for which material was
reviewed was markedly different from the diagnoses of the
sample for which no review was possible (comparing propor-
tions of osteosarcoma, sarcoma NOS and other specified
sarcoma X2 = 39.79, P = 0.00001). This difference should be
borne in mind when comparisons between Table I and Table
II are made.
Agreement between original cancer registry diagnoses andfinal
paneldiagnoses
Material was obtained and reviewed for 413 of the 450 cases
originally registered with the cancer registry as sarcomas. The
panel agreed that 313 of the 413 (76%) were sarcomas but
disagreed with the diagnosis of sarcoma in 72 cases (17%).
Twenty-one cases (5%) could be classified only as malignant
tumour NOS and the panel was unable to come to any
diagnosis in seven cases (2%).
Specific histological sub-types of sarcoma has previously
been defined for 338 of the 413 cases originally registered as
sarcomas and for which material was reviewed. The panel
agreed with the sub-type in 178 cases (53%), disagreed in 57
cases (17%) and were unable to specify a sub-type in 24
(7%). Sixty (18%) were regarded as tumours other than
sarcomas, and 12 (4%) classified only as malignant tumour
NOS. No diagnosis was given for seven cases (2%).
Cancer registry diagnosis had been non-specific for the
remaining 75 cases. Of these the panel defited a specific
histological sub-type for 42 (56%), agreed with the original
diagnosis of sarcoma NOS in 12 (16%), diagnosed the
tumour as other than sarcoma in 12 cases (16%) and were
able to diagnose only as malignant tumour NOS in nine
cases (12%).
Because of the differing biological and clinical features of
sarcomas of diverse sites, degree of agreement was also
separately measured for bone sarcomas and for soft tissue
sarcomas of visceral and non-visceral origin. Agreement on
diagnosis of sarcoma between cancer registry and panel was
87% for bone tumours, 61% for visceral tumours and 78%
for non-visceral tumours. Agreement on sub-type was 78%,
52% and 45% for bone, visceral and non-visceral tumours
respectively. Of those cases with a cancer registry diagnosis
of sarcoma NOS, 67% of bone (2/3), 40% of visceral
tumours and 61% of non-visceral tumours were given specific
sub-types by the panel. The differences between sites were
significant for diagnosis of sarcoma and diagnosis ofsub-type
(P = 0.001 in each case).
In summary, of the 315 cases with a final diagnosis of
sarcoma (313 originally selected as-sarcomas and two selected
as possible sarcomas) the cancer registry and panel agreed on
histological sub-type in 178 cases (57%) and disagreed on
sub-type in 57 (18%). In 24 cases (8%) the cancer registry
specified a sub-type but a non-specific diagnosis was given by
the panel and in 42 (13%) the panel was able to specify a
sub-type where the original diagnosis had been non-specific.
In 12 cases (4%) the original non-specific diagnosis was
upheld by the panel and in two cases (1%) the panel specified
a particular type of sarcoma where the original registered
diagnosis had been ofmalignant tumour other than sarcoma.
Because of the small numbers in each category of sarcoma,
statistical comparisons between original cancer registry diag-
nosis and final panel diagnosis were made for only five
histological sub-types. Measurement of degree of agreement
using Cohen's kappa statistic gave values of 0.38 for diag-
nosis of malignant fibrous histiocytoma, 0.55 for leiomyosar-
coma, 0.58 for liposarcoma, 0.73 for osteosarcoma and 0.81
for chondrosarcoma. The relatively low values for malignant
fibrous histiocytoma, leiomysarcoma and liposarcoma
indicate a wide discrepancy between cases originally
registered with those diagnoses and the confirmation of that
diagnosis by the panel, and also that a large proportion of
cases with a final diagnosis of these types had originally been
diagnosed as other sub-types of sarcoma. Table IV gives
further information on reclassification of tumour types for
the most commonly diagnosed tumours in the series.318 M. HARRIS et al.
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Agreement between individualpathologists andfinalpanel
diagnosis
Table V gives some measures of agreement in diagnosis
between individual pathologists (arranged in random order),
in relation to final panel diagnoses. Type A and type B
agreements were accepted for this comparison. For the 315
cases agreed upon as sarcomas by the panel, pathologist 1,
for example, saw 313 cases and diagnosed 311 of the 313
specimens as neoplastic, considered 304 to be malignant,
thought that 303 were sarcomas and specified a specific
sub-type of sarcoma which agreed with the final panel diag-
nosis in 223 cases. This pathologist reported on all 50 cases
finally diagnosed as malignant fibrous histiocytoma and
agreed with that diagnosis in 43 instances.
Discussion
Histological material was obtained for 96% (429/449) of the
468 cases entered in this study and for whom previous histo-
pathological diagnosis had been recorded. Of these, 96.7%
were reviewed by all five pathologists on the panel and final
diagnoses were arrived at for 98% (421) cases. Hence the
successful review of almost the whole population of sarcomas
diagnosed in North West England over the 3-year period
1982-84 (excluding 19 cases clinically diagnosed) enabled a
reliable assessment to be made of the results of histo-
pathological peer review.
Material was reviewed for 413 of the 450 cases originally
registered as sarcomas with the Regional Cancer Registry but
in only 313 (76%) of cases could the diagnosis of sarcoma be
confirmed by the panel. Furthermore, where a specific sub-
type of sarcoma had previously been specified the panel
agreed with the sub-type in only 53% of cases, although they
were able to specify a sub-type in 56% of previously non-
specified cases.
These results are, in general, consistent with those of
similar studies. Presant et al. (1986) reported the review of
specimens from 216 consecutive patients with bone or soft
tissue sarcomas entered into trials conducted by the
Southeastern Cancer Study Group (SEG). Most cases were
reviewed by one or two pathologists in addition to the
original reviewer, and there was agreement between primary
reviewer and panel in 66% cases. In 27% there was disagree-
ment over sub-type and 6% cases were considered not to be
sarcomas. Reports of a similar panel review of 130 cases of
disseminated soft tissue sarcoma by the Southwest Oncology
Group (Baker et al., 1978) showed total agreement on sub-
type in 62% cases, disagreement in 32% and a non-sarcoma
diagnosis in 7%. Review of 240 patients aged 15-70 years
with localised high grade soft tissue sarcomas by the Scan-
dinavian Sarcoma Group (Alvegard et al., 1989) also resulted
in change of sub-type in 25% cases and in 5% of cases being
rejected as non-sarcomas.
Change in diagnosis from sarcoma to other tumours in the
three studies described above was consistent at 5-7% cases.
One of the striking results of this study was the much larger
proportion ofcases (22%) where such a change was made. In
15% the change was to other types of malignant tumour or
malignant tumour NOS, in 3% to benign tumours, in 2% to
borderline tumours and in 2% to non-neoplastic conditions
(the remaining 2% were unclassified). The reason for this
high level of reclassification probably lies in the fact that this
was a population-based series whereas previous studies were
based upon cases referred for trials of adjuvant therapy.
Hence many of the cases in this series would not have been
referred to specialist centres for treatment because, for
example, they were very elderly, had advanced disease at
diagnosis, or were only diagnosed at post-mortem examina-
tion. In addition because of the wide geographical spread of
the cases, the original specimens had been reported by a large
number of different pathologists, some of whom would see
very few cases of sarcoma each year.
Because of small numbers, statistical measures of agree-
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Table V Agreement between individual pathologists and final panel diagnosis for cases diagnosed as sarcomas (all sites combined)
Pathologist
Diagnosis 1 2 3 4 5
(no. of cases) No. % No. % No. % No. % No. %
Neoplastic condition (315) 311/313 (99.4) 314/315 (99.7) 308/311 (99.0) 308/310 (99.4) 311/312 (99.7)
Malignant tumour (315) 304/313 (97.1) 306/315 (97.1) 299/311 (96.1) 297/310 (95.8) 304/312 (97.4)
Sarcoma (315) 303/313 (96.8) 311/315 (98.7) 298/311 (95.8) 296/310 (95.5) 297/312 (95.2)
Sarcoma sub-type where 223/277 (80.5) 238/278 (85.6) 184/275 (66.9) 178/274 (65.0) 227/276 (82.2)
specified (279)
Malignant fibrous 43/50 (86.0) 41/50 (82.0) 21/50 (42.0) 30/50 (60.0) 40/50 (80.0)
histiocytoma (50)
Leiomyosarcoma (72) 57/72 (79.2) 62/72 (86.1) 53/71 (74.6) 40/71 (56.3) 64/72 (88.9)
Liposarcoma (21) 16/20 (80.0) 19/21 (90.5) 18/21 (85.7) 16/20 (80.0) 18/20 (90.0)
Osteosarcoma (28) 21/27 (77.8) 24/27 (88.9) 18/27 (66.7) 25/28 (89.3) 21/27 (77.8)
Chondrosarcoma (28) 24/28 (85.7) 27/28 (96.4) 26/28 (92.9) 24/28 (85.7) 24/27 (88.9)
ment between the original diagnosis and the panel diagnosis
were made for only five tumour types. Degree of agreement
was high for osteosarcoma and chondrosarcoma and low for
the two sub-types most frequently diagnosed i.e. malignant
fibrous histiocytoma (MFH) and leiomyosarcoma.
MFH was the most commonly diagnosed sarcoma in
adults during the last two decades but evidence is now
accumulating that its most common variant, the pleomorphic
storiform type, is very heterogeneous and may have been
used as a diagnosis of convenience for a variety of neoplasms
in which no specific line of differentiation could be deter-
mined (Fletcher, 1990). In only 23 of the 52 cases of MFH in
this series was the diagnosis confirmed; ten were reclassified
as leiomyosarcoma and six as sarcoma NOS, perhaps
reflecting the over-utilisation of this non-specific diagnosis.
Although almost two-thirds (43/66) of the leiomyosar-
comas were confirmed as such, six were reclassified as malig-
nant tumours other than sarcomas and ten as benign or
borderline tumours. Leiomyosarcomas formed the single
largest group of sarcomas of visceral sites in this series and
degree of agreement for this sub-type was lower for tumours
of female genital tract (Cohen's kappa = 0.32) than for those
ofgastro-intestinal tract (0.44), of other soft tissue sites (0.46)
and of other visceral sites (0.63). Almost 50% of leiomyo-
sarcomas of female genital tract were in fact reclassified,
seven as leiomyomas or as smooth muscle tumours of uncer-
tain malignant potential, three as Mullerian mixed tumours
and one as endometrial stromal sarcoma. Some difficulty
however, was experienced in defining degree ofmalignancy in
these tumours particularly where sampling of tumour was felt
to be inadequate.
Diagnosis of osteosarcoma and chondrosarcoma was much
more consistent as would be expected and, in spite of its
non-specificity in appearance, there was a high degree of
agreement for Ewing's tumour with all nine cases seen by the
panel being confirmed as such.
Diagnosis of liposarcoma was very variable, with only 17
of 35 confirmed. The majority of cases of rhabdomyosar-
coma (RMS) were also reclassified (16 out of 25) on review.
This is in contrast with the findings of Newton et al. (1988)
who reported 94% agreement between the review committee
and institutional pathologists in the diagnosis of RMS,
although much less agreement on sub-type. This discrepancy
is again probably related to the type of patient entered into
the study.
Perhaps the most striking reclassification was of fibrosar-
coma with only two out of 28 cases confirmed. Five were
reclassified as MFH, four as leiomyosarcoma, five as sar-
coma NOS and the rest were spread over a variety of
different types. Fibrosarcoma was the most common sarcoma
diagnosis made 30 years ago but has perhaps been the most
affected by changing diagnostic criteria until at the present
time the diagnosis is rarely made.
The study demonstrated a high degree of agreement on the
diagnosis of sarcoma between individual pathologists on the
panel, although the diagnosis of sub-type was much less
consistent. Because, however, Type A and Type B agree-
ments were accepted for sub-type comparisons, the bias was
in favour of those pathologists who submitted more than two
differential diagnoses, rather than those whose diagnoses
were more precise. Differences between pathologists may
reflect their experience in terms of numbers of sarcomas
reviewed prior to taking part in the study and also their
differing expertise in relation to bone or soft tissue tumours.
While the degree of disagreement between original diag-
nosis and final panel diagnosis, and between individual
pathologists and the final panel diagnosis is disturbing, it
should perhaps be noted that while being a consistent finding
for histopathological studies of sarcomas, such reclassifi-
cation is much less common for most other types of malig-
nant disease (Whitehead et al., 1984).
Variation between the opinions of the original pathologist
and the panel members is inevitable. In some cases the panel
may have received unrepresentative samples of the tumour
for review, especially where there was histological variability
between areas of tumour, and in other cases inadequate
provision of different samples of the same tumour could have
resulted in the mis-diagnosis of grade of malignancy. Never-
theless it is surprising that, in spite of seeing relatively large
numbers of sarcomas over and above normal workload, such
variation in diagnosis between panel members continued to
occur and although no formal assessment of converging
agreement with time was made, the general impression was
that this did not take place. This impression is consistent
with that of Presant et al. (1986) who found no improvement
in frequency of agreement in the course of the SEG study, in
spite of educational workshops. The only conclusion which
can be drawn from this is that second opinion is of vital
importance in cases of presumed sarcomas, particularly for
those cases e.g. MFH where concordance in diagnosis appears
to be low. Review is essential so that correct treatment is
selected for those patients who are almost certain to have
sarcomas and so that inappropriate therapy is not given to
cases who do not have sarcomas, or who have only benign or
boderline or non-neoplastic conditions.
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